COMPANY PROFILE / #1628
Affinia Therapeutics
Waltham, MAVenture Capital-Backed
OVERVIEW
Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.
已融资210.00
最新估值145.00
员工数51
成立年份2019
公司概况
- Companies
- Affinia Therapeutics
- Description
- Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.
- Website
- www.affiniatx.com
- HQ Location
- Waltham, MA
- Year Founded
- 2019
- Keywords
- gene delivery, gene therapies developer, gene therapy platform, genetic medicine, therapeutic research, therapeutics platform
- Competitors
- StrideBio, Orchard Therapeutics, Autobahn Therapeutics, Voyager Therapeutics, Genetix Biotherapeutics, Audentes Therapeutics, ACADIA Pharmaceuticals
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 210.00
- First Financing Date
- 12-Mar-2020
- First Financing Size
- 60.00
- First Financing Valuation
- 100.00
- Last Financing Date
- 07-Oct-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 40.00
- Last Financing Valuation
- 145.00
- Last Financing Status
- Completed
- Last Known Valuation
- 145.00
- Last Known Valuation Date
- 07-Oct-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 196.67
- Valuation Estimate Growth Rate
- 35.63%
- Active Investors
- Alexandria Venture Investments, Atlas Venture, Avidity Partners, Casdin Capital, EcoR1 Capital, Eight Roads, Farallon Capital Management, F-Prime Capital, GV, Lilly USA, Lonza Group, Mass General Brigham Ventures, New Enterprise Associates, Octagon Capital Advisors, Perceptive Advisors, RA Capital Management, Service Provider Capital, TCG Crossover Management, Woodline Partners
- # Active Investors
- 19
- Acquirers
- —
团队与联系人
- Employees
- 51
- Employee Growth %
- -10.53% E
- Employee History
- 2025: 51, 2024: 57 E, 2023: 63, 2022: 74, 2021: 63, 2020: 33
- Primary Contact
- Rick Modi
- Primary Contact Title
- Chief Executive Officer & Board Member
- Primary Contact Email
- —
- Primary Contact Phone
- +1 (617) 430-7817
增长与经营
- Revenue
- 4.33
- Revenue Growth %
- —
- Growth Rate
- 1.50%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 99
- Size Multiple
- 4.81x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 80
- Majestic Referring Domains
- 125
- SimilarWeb Unique Visitors
- 723
- SimilarWeb Unique Visitors Change
- -123
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 22%
- Success Probability Over Time – 3 Year
- 48%
- Success Probability Over Time – 5 Year
- 59%
记录来源：public.companies · 原始序号 #1628 · 所有字段均按数据库原值展示。